Why did the Ravens back out of the Maxx Crosby trade?

What unfolded and why it matters

Baltimore reversed course on a blockbuster move after medical and procedural concerns emerged around the proposed acquisition. League reporting shows the deal collapsed when the team’s medical review raised red flags about the other side’s health documentation; multiple doctors were reportedly consulted as the club re-evaluated the risk. Within hours of walking away from the trade, Baltimore pivoted to sign a veteran edge rusher to a multi-year contract and reworked salary commitments elsewhere on the roster to create the necessary cap space.

The episode matters for several reasons. First, it left a trail of operational fallout across the league: the team that lost out on the trade (and the player involved) had to quickly re-establish a plan for integrating or rehabbing their star pass rusher; other rival clubs recalculated their own moves; and front-office reputations took a hit as league executives publicly questioned how the deal reached such an advanced stage before being canceled.

Immediate consequences include:

• The acquiring club signed an expensive free agent replacement on a long-term deal, locking in money and removing a clear target from the market.
• The original team that would have traded the player remains on the hook, needing to decide whether to reintegrate the player or pursue other trades.
• League-wide scrutiny over medical clearances and trade timelines has intensified, which could prompt procedural reviews.

Several crucial points remain unsettled. The internal deliberations that produced the reversal, the full medical findings and whether the league will open any formal inquiry are not public. What is clear is that one dramatic front-office decision reshaped multiple rosters and created a ripple effect that will be felt through free agency, the draft and team planning in the weeks ahead.